Back to Search
Start Over
Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.
- Source :
-
Leukemia [Leukemia] 2019 Mar; Vol. 33 (3), pp. 762-808. Date of Electronic Publication: 2018 Oct 05. - Publication Year :
- 2019
Details
- Language :
- English
- ISSN :
- 1476-5551
- Volume :
- 33
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Leukemia
- Publication Type :
- Academic Journal
- Accession number :
- 30291334
- Full Text :
- https://doi.org/10.1038/s41375-018-0277-8